-
Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
According to AI News, according to CNBC, Lilly has applied to the United States for approval of its weight loss drug Zepbound for the treatment of the most common sleep related respiratory disorders, ... -
Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
On September 27th, Sanofi announced that Dapitumab Injection has been approved by the China National Medical Products Administration for use in adult patients with chronic obstructive pulmonary disea ...